NO20014415D0 - Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens - Google Patents

Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens

Info

Publication number: NO20014415D0
Authority: NO; Norway
Prior art keywords: gal; preparations; methods; alfa; galactosidase
Prior art date: 1999-03-11

Application number

NO20014415A

Other languages

English (en)

Other versions

NO20014415L (no

NO329689B1 (no

Inventor

Richard F Selden

Marianne Borowski

Carol M Kinoshita

Douglas A Treco

Melanie D Williams

Thomas J Schuetz

Peter Francis Daniel

Original Assignee

Transkaryotic Therapies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-11

Filing date

2001-09-11

Publication date

2001-09-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23012821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20014415(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-09-11 Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc

2001-09-11 Publication of NO20014415D0 publication Critical patent/NO20014415D0/no

2001-11-12 Publication of NO20014415L publication Critical patent/NO20014415L/no

2010-11-29 Publication of NO329689B1 publication Critical patent/NO329689B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Neurology (AREA)
Cardiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)

NO20014415A 1999-03-11 2001-09-11 Medisinske preparater til behandling av <alfa>-galaktosidase-A-defisiens NO329689B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/266,014 US6458574B1 (en)	1996-09-12	1999-03-11	Treatment of a α-galactosidase a deficiency
PCT/US2000/006118 WO2000053730A2 (en)	1999-03-11	2000-03-09	Medical preparations for the treatment of alpha-galactosidase a deficiency

Publications (3)

Publication Number	Publication Date
NO20014415D0 true NO20014415D0 (no)	2001-09-11
NO20014415L NO20014415L (no)	2001-11-12
NO329689B1 NO329689B1 (no)	2010-11-29

Family

ID=23012821

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20014415A NO329689B1 (no)	1999-03-11	2001-09-11	Medisinske preparater til behandling av <alfa>-galaktosidase-A-defisiens
NO20101493A NO20101493L (no)	1999-03-11	2010-10-22	Medisinske preparater til behandling av alfa-galaktosidase-A-defisiens

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20101493A NO20101493L (no)	1999-03-11	2010-10-22	Medisinske preparater til behandling av alfa-galaktosidase-A-defisiens

Country Status (22)

Country	Link
US (4)	US6458574B1 (no)
EP (6)	EP2314699B1 (no)
JP (6)	JP2002538183A (no)
KR (2)	KR100892334B1 (no)
CN (4)	CN101219213A (no)
AT (1)	ATE386808T1 (no)
AU (1)	AU3519400A (no)
CA (3)	CA2365923A1 (no)
CY (3)	CY1107951T1 (no)
DE (1)	DE60038104T2 (no)
DK (3)	DK2186902T3 (no)
ES (3)	ES2391221T3 (no)
HK (3)	HK1043386B (no)
HU (1)	HU228743B1 (no)
IL (2)	IL145381A0 (no)
MX (1)	MXPA01009222A (no)
NO (2)	NO329689B1 (no)
NZ (1)	NZ514077A (no)
PL (1)	PL210833B1 (no)
PT (3)	PT2314699T (no)
RU (1)	RU2248213C2 (no)
WO (1)	WO2000053730A2 (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
US6083725A (en) *	1996-09-13	2000-07-04	Transkaryotic Therapies, Inc.	Tranfected human cells expressing human α-galactosidase A protein
IL155588A0 (en) *	2003-04-27	2003-11-23	Metabogal Ltd	Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) *	1996-09-26	2005-02-10	Metabogal Ltd.	Cell/tissue culturing device, system and method
US7629309B2 (en)	2002-05-29	2009-12-08	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
ES2300439T3 (es) *	2001-04-30	2008-06-16	Zystor Therapeutics , Inc.	Reconocimiento subcelular de proteinas terapeuticas.
US20040005309A1 (en) *	2002-05-29	2004-01-08	Symbiontics, Inc.	Targeted therapeutic proteins
US7560424B2 (en)	2001-04-30	2009-07-14	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US20030072761A1 (en)	2001-10-16	2003-04-17	Lebowitz Jonathan	Methods and compositions for targeting proteins across the blood brain barrier
EP2361631A1 (en)	2002-04-25	2011-08-31	Shire Human Genetic Therapies, Inc.	Treatment of alpha-galactosidase a deficiency
WO2006002283A1 (en) *	2004-06-21	2006-01-05	Medtronic, Inc.	Medical systems and methods for delivering compositions to cells
SI2444102T1 (sl)	2003-01-31	2015-08-31	Mount Sinai School Of Medicine Of New York University	Kombinirana terapija za zdravljenje motenj pomanjkanja proteina
US7422310B2 (en) *	2003-04-25	2008-09-09	Hewlett-Packard Development Company, L.P.	Methods and apparatus for selecting image enhancement techniques
US7951557B2 (en) *	2003-04-27	2011-05-31	Protalix Ltd.	Human lysosomal proteins from plant cell culture
US20100196345A1 (en) *	2003-04-27	2010-08-05	Protalix	Production of high mannose proteins in plant culture
US7442372B2 (en) *	2003-08-29	2008-10-28	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
CA2553955C (en)	2004-02-10	2012-08-28	Zystor Therapeutics, Inc.	Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) *	2004-03-18	2005-09-22	Medtronic, Inc.	Methods and systems for treatment of neurological diseases of the central nervous system
CN1308444C (zh) *	2005-04-15	2007-04-04	中国人民解放军军事医学科学院野战输血研究所	基因重组α－半乳糖苷酶大批量发酵液的纯化方法
AU2006247065B8 (en)	2005-05-17	2012-07-12	Amicus Therapeutics, Inc.	A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
JP4368925B2 (ja)	2005-11-18	2009-11-18	財団法人東京都医学研究機構	基質特異性を変換した新規高機能酵素
WO2007086067A1 (en) *	2006-01-30	2007-08-02	Diagnostic Technologies Ltd.	Method for monitoring tocolytic treatment
JP2010509344A (ja) *	2006-11-13	2010-03-25	ザイストールセラピューティクス，インコーポレイテッド	ポンペ病を治療するための方法
RU2468076C2 (ru) *	2007-05-07	2012-11-27	Проталикс Лтд.	Одноразовое устройство для культивирования и сбора растительной ткани и/или клеток, способ и система культивирования и сбора растительной ткани и/или растительных клеток
EP2185187A1 (en) *	2007-08-29	2010-05-19	Shire Human Genetic Therapies, Inc.	Subcutaneous administration of alpha-galatosidase a
EP3187508A1 (en)	2008-05-07	2017-07-05	BioMarin Pharmaceutical Inc.	Lysosomal targeting peptides and uses thereof
US9050276B2 (en)	2009-06-16	2015-06-09	The Trustees Of Columbia University In The City Of New York	Autism-associated biomarkers and uses thereof
EP2475376B1 (en)	2009-06-17	2016-03-30	BioMarin Pharmaceutical Inc.	Formulations for lysosomal enzymes
US9194011B2 (en)	2009-11-17	2015-11-24	Protalix Ltd.	Stabilized alpha-galactosidase and uses thereof
ES2606532T3 (es) *	2010-03-02	2017-03-24	Protalix Ltd.	Alfa-galactosidasa estabilizada y usos de la misma
US20110293585A1 (en) *	2010-04-21	2011-12-01	Helix Therapeutics, Inc.	Compositions and methods for treatment of lysosomal storage disorders
EA029503B1 (ru)	2010-07-08	2018-04-30	Баксалта Инкорпорейтид	Способ получения рекомбинантного adamts13 в культуре клеток
EP2627349B1 (en)	2010-10-15	2016-02-03	The Trustees of Columbia University in the City of New York	Obesity-related genes and their proteins and uses thereof
HUE045869T2 (hu)	2010-11-02	2020-01-28	Univ Columbia	Módszerek hajhullásos rendellenességek kezelésére
BR112013022277B1 (pt)	2011-03-04	2021-08-03	Glytech, Inc	Método para produção de cadeia de açúcar contendo ácido siálico
DK3586861T3 (da)	2011-06-08	2022-04-25	Translate Bio Inc	Lipidnanopartikelsammensætninger og fremgangsmåder til mrna-indgivelse
MX349992B (es)	2012-03-07	2017-08-22	Amicus Therapeutics Inc	Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe.
WO2013139861A1 (en)	2012-03-20	2013-09-26	Luc Montagnier	Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
DK2830662T3 (da)	2012-03-29	2019-01-02	Univ Columbia	Fremgangsmåder til behandlng af hårtabsforstyrrelser
WO2014014938A1 (en) *	2012-07-17	2014-01-23	Amicus Therapeutics, Inc.	Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
US10155027B2 (en)	2012-07-17	2018-12-18	Amicus Therapeutics, Inc.	Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014016873A1 (en)	2012-07-26	2014-01-30	Jcr Pharmaceuticals Co., Ltd.	Method for production of recombinant human alpha-galactosidase a
JP6226435B2 (ja) *	2012-07-26	2017-11-08	Ｊｃｒファーマ株式会社	組換えヒトα−ガラクトシダーゼＡの製造方法
WO2014120900A1 (en) *	2013-01-31	2014-08-07	Icahn School Of Medicine At Mount Sinai	Enhanced therapeutic regimens for treating fabry disease
MX2015011944A (es)	2013-03-14	2015-12-01	Shire Human Genetic Therapies	Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
EP2971098B1 (en)	2013-03-14	2018-11-21	Translate Bio, Inc.	Quantitative assessment for cap efficiency of messenger rna
TWI642782B (zh)	2013-10-23	2018-12-01	健臻公司	重組醣蛋白及其用途
US9682123B2 (en)	2013-12-20	2017-06-20	The Trustees Of Columbia University In The City Of New York	Methods of treating metabolic disease
MY188028A (en) *	2014-03-05	2021-11-10	Ultragenyx Pharmaceutical Inc	Sialylated glycoprotein compositions and uses thereof
SG10202003753PA (en)	2014-09-30	2020-05-28	Amicus Therapeutics Inc	Highly potent acid alpha-glucosidase with enhanced carbohydrates
US20170360900A1 (en)	2014-12-22	2017-12-21	Codexis, Inc.	Human alpha-galactosidase variants
IL253071B2 (en) *	2014-12-22	2024-04-01	Genzyme Corp	Methods for growing mammalian cells
WO2016116966A1 (en)	2015-01-22	2016-07-28	Jcr Pharmaceuticals Co., Ltd.	Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
US9981021B1 (en)	2015-04-09	2018-05-29	Kinetiq, Inc.	Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en)	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
AU2016321298A1 (en)	2015-09-09	2018-03-29	The Trustees Of Columbia University In The City Of New York	Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
WO2017117407A1 (en)	2015-12-30	2017-07-06	Amicus Therapeutics, Inc.	Augmented acid alpha-glucosidase for the treatment of pompe disease
CA3014792A1 (en)	2016-02-16	2017-08-24	Carnegie Mellon University	Compositions for enhancing targeted gene editing and methods of use thereof
BR112018069965A2 (pt)	2016-03-30	2019-01-29	Amicus Therapeutics Inc	formulações compreendendo alfa-glucosidase ácida recombinante
BR112018070189A2 (pt)	2016-03-30	2019-02-19	Amicus Therapeutics, Inc.	método para seleção de proteínas recombinantes ricas em m6p
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
US11154591B2 (en)	2016-10-14	2021-10-26	The Trustees Of Columbia University In The City Of New York	Methods of treating alcohol abuse disorder
CN110022904B (zh) *	2016-10-20	2024-04-19	桑格摩生物治疗股份有限公司	用于治疗法布里病的方法和组合物
JP2020503900A (ja) *	2017-01-10	2020-02-06	アミカスセラピューティックスインコーポレイテッド	ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ
EA202290114A1 (ru) *	2017-03-30	2022-03-29	Амикус Терапьютикс, Инк.	Способ отбора рекомбинантных белков с высоким содержанием m6p
CN119113091A (zh)	2017-05-15	2024-12-13	阿米库斯治疗学公司	重组人类酸性α-葡萄糖苷酶
WO2020047282A1 (en) *	2018-08-29	2020-03-05	University Of Copenhagen	Lysosomal enzymes modified by cell based glycoengineering
BR112021011750A2 (pt)	2018-12-20	2021-08-31	Codexis, Inc.	Alfa-galactosidase a recombinante e/ou fragmento de alfa-galactosidase a recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa-galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições
EP3996696A1 (en)	2019-07-09	2022-05-18	Genethon	Treatment of glycogen storage disease (gsd)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5322158B2 (no) *	1974-05-02	1978-07-06
US4407957A (en)	1981-03-13	1983-10-04	Damon Corporation	Reversible microencapsulation of a core material
US4740365A (en)	1984-04-09	1988-04-26	Toyo Boseki Kabushiki Kaisha	Sustained-release preparation applicable to mucous membrane in oral cavity
US4764376A (en)	1984-06-18	1988-08-16	Eli Lilly And Company	Method of inhibiting aromatase
GB8530631D0 (en) *	1985-12-12	1986-01-22	Ciba Geigy Ag	Thrombin inhibitors
US4764378A (en)	1986-02-10	1988-08-16	Zetachron, Inc.	Buccal drug dosage form
US5272066A (en) *	1986-03-07	1993-12-21	Massachusetts Institute Of Technology	Synthetic method for enhancing glycoprotein stability
US5179023A (en) *	1989-03-24	1993-01-12	Research Corporation Technologies, Inc.	Recombinant α-galactosidase a therapy for Fabry disease
EP0463109A4 (en)	1989-03-24	1992-11-19	Research Corporation Technologies, Inc.	Recombinant alpha-galactosidase, a therapy for fabry disease
US5382518A (en) *	1989-07-13	1995-01-17	Sanofi	Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
ATE154362T1 (de) *	1989-09-05	1997-06-15	Biotech Australia Pty Ltd	Verfahren zur herstellung von pai-2
US5697901A (en) *	1989-12-14	1997-12-16	Elof Eriksson	Gene delivery by microneedle injection
US5661132A (en) *	1989-12-14	1997-08-26	Auragen, Inc.	Wound healing
US5356804A (en)	1990-10-24	1994-10-18	Mount Sinai School Of Medicine Of The City Of New York	Cloning and expression of biologically active human α-galactosidase A
US5401650A (en) *	1990-10-24	1995-03-28	The Mount Sinai School Of Medicine Of The City University Of New York	Cloning and expression of biologically active α-galactosidase A
DK0585368T3 (da)	1991-04-25	1998-03-16	Univ Brown Res Found	Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
AU662919B2 (en)	1991-07-02	1995-09-21	Inhale, Inc.	Method and device for delivering aerosolized medicaments
US5750376A (en)	1991-07-08	1998-05-12	Neurospheres Holdings Ltd.	In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
PT101031B (pt)	1991-11-05	2002-07-31	Transkaryotic Therapies Inc	Processo para o fornecimento de proteinas por terapia genetica
US5733761A (en)	1991-11-05	1998-03-31	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US5858751A (en)	1992-03-09	1999-01-12	The Regents Of The University Of California	Compositions and methods for producing sialyltransferases
DK0641192T3 (da)	1992-05-18	1998-03-02	Minnesota Mining & Mfg	Anordning til transmucosal lægemiddelafgivelse
US5785049A (en)	1994-09-21	1998-07-28	Inhale Therapeutic Systems	Method and apparatus for dispersion of dry powder medicaments
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US5804413A (en)	1992-07-31	1998-09-08	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Herpes simplex virus strains for gene transfer
US5569189A (en)	1992-09-28	1996-10-29	Equidyne Systems, Inc.	hypodermic jet injector
DE69332105T2 (de)	1992-09-29	2003-03-06	Inhale Therapeutic Systems, San Carlos	Pulmonale abgabe von aktiven fragmenten des parathormons
US5389539A (en)	1992-11-30	1995-02-14	Massachusetts Institute Of Technology	Purification of heparinase I, II, and III from Flavobacterium heparinum
US6329191B1 (en)	1993-08-30	2001-12-11	Hawaii Biotechnology Group, Inc.	DNA encoding recombinant coffee bean alpha-galactosidase
EP0726964A4 (en) *	1993-09-23	1999-01-13	New England Biolabs Inc	INSULATION AND COMPOSITION OF NEW GLYCOSIDASES
DE4339605A1 (de)	1993-11-20	1995-05-24	Beiersdorf Ag	Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5843015A (en)	1993-12-28	1998-12-01	Becton Dickinson And Company	Molecules for iontophoretic delivery
US5789247A (en)	1994-04-01	1998-08-04	Ballay; Annick	Expression in non-tumoral human lymphoblastoid lines with an integrative vector
FR2718357B1 (fr)	1994-04-06	1997-10-03	Defarges Alain Moreau	Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5834251A (en) *	1994-12-30	1998-11-10	Alko Group Ltd.	Methods of modifying carbohydrate moieties
US5599302A (en)	1995-01-09	1997-02-04	Medi-Ject Corporation	Medical injection system and method, gas spring thereof and launching device using gas spring
EP0807165A4 (en) *	1995-01-30	1998-07-15	New York Blood Center Inc	ENZYME -g (a) -GALACTOSIDASE RECOMBINANT
US5780014A (en)	1995-04-14	1998-07-14	Inhale Therapeutic Systems	Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en)	1995-06-07	1997-08-05	Inhale Therapeutic Systems	Methods and system for processing dispersible fine powders
US6566089B1 (en) *	1996-09-04	2003-05-20	Tularik Inc.	Cell-based drug screens for regulators of gene expression
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
US6083725A (en) *	1996-09-13	2000-07-04	Transkaryotic Therapies, Inc.	Tranfected human cells expressing human α-galactosidase A protein
RU2179034C2 (ru)	1996-09-13	2002-02-10	Транскариотик Терапиз, Инк.	ЛЕЧЕНИЕ В СЛУЧАЕ ДЕФИЦИТА α-ГАЛАКТОЗИДАЗЫ А
IL125423A (en) *	1998-07-20	2004-08-31	Israel State	Alkaline alpha-galactosidase having broad substrate specificity
US6749851B2 (en) *	2001-08-31	2004-06-15	Clearant, Inc.	Methods for sterilizing preparations of digestive enzymes

1999
- 1999-03-11 US US09/266,014 patent/US6458574B1/en not_active Expired - Lifetime
2000
- 2000-03-09 DE DE60038104T patent/DE60038104T2/de not_active Expired - Lifetime
- 2000-03-09 AU AU35194/00A patent/AU3519400A/en not_active Abandoned
- 2000-03-09 EP EP10180768.3A patent/EP2314699B1/en not_active Expired - Lifetime
- 2000-03-09 AT AT00913825T patent/ATE386808T1/de active
- 2000-03-09 RU RU2001127533/15A patent/RU2248213C2/ru active
- 2000-03-09 CN CNA2007101482923A patent/CN101219213A/zh not_active Withdrawn
- 2000-03-09 CA CA002365923A patent/CA2365923A1/en active Pending
- 2000-03-09 DK DK10152432.0T patent/DK2186902T3/da active
- 2000-03-09 CA CA2833396A patent/CA2833396C/en not_active Expired - Lifetime
- 2000-03-09 EP EP10152432A patent/EP2186902B1/en not_active Revoked
- 2000-03-09 ES ES10152432T patent/ES2391221T3/es not_active Expired - Lifetime
- 2000-03-09 CN CNB008073120A patent/CN100417727C/zh not_active Expired - Lifetime
- 2000-03-09 PT PT101807683T patent/PT2314699T/pt unknown
- 2000-03-09 HU HU0200467A patent/HU228743B1/hu unknown
- 2000-03-09 MX MXPA01009222A patent/MXPA01009222A/es active IP Right Grant
- 2000-03-09 NZ NZ514077A patent/NZ514077A/xx not_active IP Right Cessation
- 2000-03-09 KR KR1020017011552A patent/KR100892334B1/ko active IP Right Grant
- 2000-03-09 ES ES10180768.3T patent/ES2634317T3/es not_active Expired - Lifetime
- 2000-03-09 JP JP2000603353A patent/JP2002538183A/ja active Pending
- 2000-03-09 ES ES00913825T patent/ES2300256T3/es not_active Expired - Lifetime
- 2000-03-09 EP EP10180757A patent/EP2287319A1/en not_active Withdrawn
- 2000-03-09 KR KR1020077019031A patent/KR100961740B1/ko active IP Right Grant
- 2000-03-09 IL IL14538100A patent/IL145381A0/xx unknown
- 2000-03-09 CA CA3012663A patent/CA3012663A1/en not_active Expired - Lifetime
- 2000-03-09 DK DK00913825T patent/DK1163349T3/da active
- 2000-03-09 PT PT10152432T patent/PT2186902E/pt unknown
- 2000-03-09 PL PL350658A patent/PL210833B1/pl unknown
- 2000-03-09 CN CN201310243356.3A patent/CN103585621B/zh not_active Expired - Lifetime
- 2000-03-09 PT PT00913825T patent/PT1163349E/pt unknown
- 2000-03-09 EP EP06025159A patent/EP1820862A3/en not_active Ceased
- 2000-03-09 CN CN201610478912.9A patent/CN106110309A/zh active Pending
- 2000-03-09 WO PCT/US2000/006118 patent/WO2000053730A2/en active IP Right Grant
- 2000-03-09 EP EP00913825A patent/EP1163349B1/en not_active Expired - Lifetime
- 2000-03-09 EP EP17169335.1A patent/EP3231871A1/en not_active Withdrawn
- 2000-03-09 DK DK10180768.3T patent/DK2314699T3/en active
2001
- 2001-09-11 IL IL145381A patent/IL145381A/en not_active IP Right Cessation
- 2001-09-11 NO NO20014415A patent/NO329689B1/no not_active IP Right Cessation
2002
- 2002-06-07 US US10/165,060 patent/US20030077806A1/en not_active Abandoned
- 2002-06-10 US US10/165,968 patent/US20030113894A1/en not_active Abandoned
- 2002-06-11 HK HK02104366.6A patent/HK1043386B/zh not_active IP Right Cessation
2008
- 2008-05-20 CY CY20081100521T patent/CY1107951T1/el unknown
2010
- 2010-09-27 JP JP2010215000A patent/JP5615648B2/ja not_active Expired - Lifetime
- 2010-10-22 NO NO20101493A patent/NO20101493L/no not_active Application Discontinuation
- 2010-11-03 HK HK10110284.2A patent/HK1143833A1/xx not_active IP Right Cessation
- 2010-11-11 US US12/944,688 patent/US20110280856A1/en not_active Abandoned
2012
- 2012-08-10 CY CY20121100736T patent/CY1113051T1/el unknown
2013
- 2013-08-26 JP JP2013174418A patent/JP5899169B2/ja not_active Expired - Lifetime
2014
- 2014-12-16 JP JP2014254079A patent/JP6081980B2/ja not_active Expired - Lifetime
2016
- 2016-10-12 JP JP2016200833A patent/JP6346236B2/ja not_active Expired - Lifetime
2017
- 2017-07-26 CY CY20171100801T patent/CY1119369T1/el unknown
- 2017-11-15 JP JP2017219734A patent/JP6626071B2/ja not_active Expired - Lifetime
2018
- 2018-04-03 HK HK18104453.2A patent/HK1245320A1/zh unknown

Also Published As

Publication number	Publication date
CY1107951T1 (el)	2013-09-04
DE60038104T2 (de)	2009-02-12
HU228743B1 (en)	2013-05-28
ES2300256T3 (es)	2008-06-16
US20030113894A1 (en)	2003-06-19
DK1163349T3 (da)	2008-06-23
EP3231871A1 (en)	2017-10-18
JP6626071B2 (ja)	2019-12-25
KR20070090277A (ko)	2007-09-05
JP2017014279A (ja)	2017-01-19
JP2018038423A (ja)	2018-03-15
KR100961740B1 (ko)	2010-06-07
HK1245320A1 (zh)	2018-08-24
CY1113051T1 (el)	2016-04-13
US20110280856A1 (en)	2011-11-17
US20030077806A1 (en)	2003-04-24
JP5899169B2 (ja)	2016-04-06
CY1119369T1 (el)	2018-02-14
AU3519400A (en)	2000-09-28
HK1043386B (zh)	2008-06-13
HK1143833A1 (en)	2011-01-14
NO20101493L (no)	2001-11-12
WO2000053730A2 (en)	2000-09-14
JP2015091834A (ja)	2015-05-14
ES2391221T3 (es)	2012-11-22
EP2314699B1 (en)	2017-05-31
CA2833396C (en)	2018-08-28
CN100417727C (zh)	2008-09-10
MXPA01009222A (es)	2002-06-04
CN103585621B (zh)	2016-08-10
PT2314699T (pt)	2017-08-01
WO2000053730A3 (en)	2001-03-15
CN103585621A (zh)	2014-02-19
DK2186902T3 (da)	2012-09-03
KR20020021371A (ko)	2002-03-20
EP1163349A2 (en)	2001-12-19
NZ514077A (en)	2004-02-27
ES2634317T3 (es)	2017-09-27
EP2186902A2 (en)	2010-05-19
NO20014415L (no)	2001-11-12
RU2248213C2 (ru)	2005-03-20
CA3012663A1 (en)	2000-09-14
JP2013241466A (ja)	2013-12-05
CA2833396A1 (en)	2000-09-14
PL210833B1 (pl)	2012-03-30
HUP0200467A2 (en)	2002-06-29
EP2314699A1 (en)	2011-04-27
JP2011037867A (ja)	2011-02-24
ATE386808T1 (de)	2008-03-15
IL145381A (en)	2009-12-24
PL350658A1 (en)	2003-01-27
JP2002538183A (ja)	2002-11-12
JP6081980B2 (ja)	2017-02-15
JP6346236B2 (ja)	2018-06-20
PT1163349E (pt)	2008-05-19
CN1354796A (zh)	2002-06-19
EP1820862A3 (en)	2007-10-31
WO2000053730A9 (en)	2001-10-11
EP1163349B1 (en)	2008-02-20
US6458574B1 (en)	2002-10-01
CN101219213A (zh)	2008-07-16
EP1820862A2 (en)	2007-08-22
EP2186902A3 (en)	2010-09-01
DE60038104D1 (de)	2008-04-03
CN106110309A (zh)	2016-11-16
EP2186902B1 (en)	2012-05-23
HK1043386A1 (en)	2002-09-13
DK2314699T3 (en)	2017-08-07
PT2186902E (pt)	2012-08-28
KR100892334B1 (ko)	2009-04-08
IL145381A0 (en)	2002-06-30
CA2365923A1 (en)	2000-09-14
NO329689B1 (no)	2010-11-29
JP5615648B2 (ja)	2014-10-29
EP2287319A1 (en)	2011-02-23
HUP0200467A3 (en)	2006-06-28

Publication	Publication Date	Title
NO20014415D0 (no)	2001-09-11	Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
TR199800012T1 (xx)	1998-04-21	Piroloprimidinler ve preparasyon i�in tatbikler.
EA200000759A1 (ru)	2001-04-23	Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE69838986D1 (de)	2008-02-21	Polypeptide, deren herstellung und verwendung
MY155218A (en)	2015-09-30	Small molecules useful in the treatment of inflammatory disease
ATE232396T1 (de)	2003-02-15	Oxydiertes thymosin beta 4
ATE197670T1 (de)	2000-12-15	Parenterales busulfan zur behandlung von malignen krankheiten
FI972308A0 (fi)	1997-05-30	2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
YU68702A (sh)	2006-01-16	Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
DE69821498D1 (de)	2004-03-11	Verwendung von amifostin
ATE188873T1 (de)	2000-02-15	Tris-platin-komplexe
DE60222383D1 (de)	2007-10-25	Medikament zur verabreichung von amifostin und verwandten wirkstoffen
ATE172721T1 (de)	1998-11-15	Aminosäurederivate und ihre verwendung als enkephalinase-inhibitoren
MX9403032A (es)	1995-01-31	Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
DE50114335D1 (de)	2008-10-30	Lh-rh-antagonisten, deren herstellung und verwendung als arzneimittel
ATE5256T1 (de)	1983-11-15	Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
DE3767731D1 (de)	1991-03-07	Prostacyclinanalog, dieses als aktives bestandteil enthaltendes, den blutumlauf verbesserndes mittel und gegen magengeschwuere wirkendes mittel.
NO20020914D0 (no)	2002-02-25	Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav
ATE106732T1 (de)	1994-06-15	Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
NO20001812D0 (no)	2000-04-07	Gallesyresalter av metaller med fysiologisk virkning, samt terapeutisk anvendelse derav
ATE222103T1 (de)	2002-08-15	Inklusionskomplexe in waessriger loesung
WO1999003509A3 (de)	1999-05-14	Pharmazeutische mittel enthaltend perfluoralkylgruppenhaltige trijodaromaten und ihre verwendung in der tumortherapie und interventionellen radiologie
NIKOLOVA	1998	THE RIGHTS OF THE HANDICAPPED PERSONS IN CASE OF THE LOW FOR SOCIAL CARE
NO20015207D0 (no)	2001-10-25	Anvendelse av antiprogestagener i kombinert terapi
DE3687448D1 (de)	1993-02-18	Verwendung von 6h-7,8-dihydrothiapyrano(3,2d)pyrimidinen zur herstellung von arzneimitteln zur verwendung als hypoglykaemische mittel oder als abmagerungsmittel fuer fettsuechtige patienten.

Legal Events

Date	Code	Title	Description
2020-04-14	MK1K	Patent expired